BIO vs. ICLR: Bio-Rad Laboratories vs. ICON Stock Comparison
How do Bio-Rad Laboratories (BIO) and ICON (ICLR) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Bio-Rad Laboratories (BIO) and ICON (ICLR) are both classified in the Life Sciences Tools & Services sub-industry within the broader Life Sciences Tools & Services industry, placing them in the closest GICS peer bucket.
| Profile Item | BIO | ICLR |
|---|---|---|
| Name | Bio-Rad Laboratories Inc. | ICON plc |
| Country/Region | United States | Ireland |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Life Sciences Tools & Services | Life Sciences Tools & Services |
| GICS Sub-Industry | Life Sciences Tools & Services | Life Sciences Tools & Services |
| Market Capitalization | 10.26 billion USD | 15.34 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | Nasdaq |
| Listing Date | February 27, 1980 | May 15, 1998 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | BIO | ICLR |
|---|---|---|
| Total Return (1Y) | 28.31% | 30.55% |
| Total Return (3Y, Annualized) | 8.52% | -6.05% |
| Total Return (5Y, Annualized) | -11.74% | -5.40% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | BIO | ICLR |
|---|---|---|
| Volatility (1Y, Annualized) | 36.50% | 68.62% |
| Beta (5Y) | 1.03 | 1.17 |
| Max Drawdown (5Y) | -72.24% | -76.87% |
| Avg. Volume (3M) | 250.78K | 943.50K |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | BIO | ICLR |
|---|---|---|
| Sharpe Ratio (1Y) | 0.66 | 0.38 |
| Sortino Ratio (1Y) | 0.98 | 0.52 |
Profitability
ROE (TTM)
Bio-Rad Laboratories (BIO) at 14.27% sits in the top ROE quartile, while ICON (ICLR) at 4.70% is closer to the peer norm — stronger capital efficiency for BIO.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
14.27%
- Max
- 109.18%
- BIO
- 14.27%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.70%
- Max
- 109.18%
- Q3
- 6.23%
- ICLR
- 4.70%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Bio-Rad Laboratories (BIO) at 39.45% keeps the most of each sales dollar — above its industry’s net margin range — and ICON (ICLR) at 5.26% also retains a top-quartile share.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
39.45%
- BIO
- 39.45%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.26%
- Max
- 18.05%
- ICLR
- 5.26%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Bio-Rad Laboratories (BIO) at 11.82% and ICON (ICLR) at 10.73% run core operations about as efficiently as their industries’ norm — neither stands out on operating profitability.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
11.82%
- Max
- 83.12%
- Q3
- 14.77%
- BIO
- 11.82%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
10.73%
- Max
- 83.12%
- Q3
- 14.77%
- ICLR
- 10.73%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | BIO | ICLR |
|---|---|---|
| ROE (TTM) | 14.27% | 4.70% |
| ROA (TTM) | 1.50% | 0.85% |
| Net Margin (TTM) | 39.45% | 5.26% |
| Operating Margin (TTM) | 11.82% | 10.73% |
| Gross Margin (TTM) | 52.19% | 23.44% |
Growth
Revenue Growth
Both Bio-Rad Laboratories (BIO) at 0.65% and ICON (ICLR) at 0.76% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Only one side can be read here: ICON (ICLR) reports EPS growth of -71.56%, ranked against its industry; Bio-Rad Laboratories (BIO) has no EPS growth figure this period.
Growth Metrics
| Metric | BIO | ICLR |
|---|---|---|
| Revenue Growth (YoY) | 0.65% | 0.76% |
| Revenue Growth (3Y CAGR) | -2.68% | 2.15% |
| EPS Growth (YoY) | -- | -71.56% |
| EPS Growth (3Y CAGR) | -- | -23.82% |
Financial Strength
Current Ratio (MRQ)
Bio-Rad Laboratories (BIO) at 3.18 keeps current ratio within its industry’s typical mid-range, while ICON (ICLR) at 1.32 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for ICLR.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.18
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- BIO
- 3.18
- Q1
- 2.47
- Min
- 0.10
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.32
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- ICLR
- 1.32
- Min
- 0.10
Debt / Equity (MRQ)
Both Bio-Rad Laboratories (BIO) at 0.18 and ICON (ICLR) at 0.38 fund their balance sheets with roughly industry-typical debt-to-equity mixes.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.18
- Max
- 1.42
- Q3
- 0.65
- BIO
- 0.18
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.38
- Max
- 1.42
- Q3
- 0.65
- ICLR
- 0.38
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | BIO | ICLR |
|---|---|---|
| Current Ratio (MRQ) | 3.18 | 1.32 |
| Debt / Equity (MRQ) | 0.18 | 0.38 |
| Net Debt / EBITDA | -0.73 | 5.55 |
Dividends
Dividend Yield (TTM)
Neither Bio-Rad Laboratories (BIO) nor ICON (ICLR) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BIO
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ICLR
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Bio-Rad Laboratories (BIO) nor ICON (ICLR) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BIO
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ICLR
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | BIO | ICLR |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
Bio-Rad Laboratories (BIO) at 10.14 sits in the cheaper P/E ratio quartile, while ICON (ICLR) at 81.90 sits in the richer quartile — a clear split in what investors pay for each dollar of trailing earnings.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
10.14
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- BIO
- 10.14
- Min
- 0.07
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
81.90
- Max
- 85.34
- ICLR
- 81.90
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
ICON (ICLR) at 1.86 sits in the cheaper P/S ratio quartile while Bio-Rad Laboratories (BIO) at 3.96 prices around its industry’s middle — ICLR costs less per dollar of sales, though read it alongside growth and margins.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.96
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- BIO
- 3.96
- Q1
- 3.01
- Min
- 0.01
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.86
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- ICLR
- 1.86
- Min
- 0.01
P/B Ratio (MRQ)
Relative to net asset value, both Bio-Rad Laboratories (BIO) at 1.35 and ICON (ICLR) at 1.68 look inexpensive, sitting in the lower P/B ratio quartile of their industries.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.35
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- BIO
- 1.35
- Min
- -5.59
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.68
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- ICLR
- 1.68
- Min
- -5.59
Valuation Metrics
| Metric | BIO | ICLR |
|---|---|---|
| P/E Ratio (TTM) | 10.14 | 81.90 |
| P/S Ratio (TTM) | 3.96 | 1.86 |
| P/B Ratio (MRQ) | 1.35 | 1.68 |
| Free Cash Flow Yield (TTM) | 2.65% | 3.51% |